TherapeuticsMD Inc
$ 1.61
1.26%
04 Dec - close price
- Market Cap 18,403,200 USD
- Current Price $ 1.61
- High / Low $ 1.63 / 1.50
- Stock P/E 159.00
- Book Value 2.37
- EPS 0.01
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE N/A %
- 52 Week High 2.10
- 52 Week Low 0.70
About
TherapeuticsMD, Inc. is an innovative women's healthcare company headquartered in Boca Raton, Florida, dedicated to addressing critical needs in hormone therapy and contraception through its advanced prescription medications. By leveraging a strong pipeline and a focused research and development strategy, the company aims to provide transformative health solutions that significantly improve women's quality of life at various life stages. Positioned at the forefront of women's health, TherapeuticsMD is committed to pioneering advancements that not only meet unmet medical needs but also contribute meaningfully to the overall healthcare ecosystem.
Analyst Target Price
$5.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-11-12 | 2024-08-12 | 2024-05-10 | 2024-03-29 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-27 |
| Reported EPS | 0 | 0.05 | 0.0219 | 0.0219 | -0.0528 | -0.0945 | -0.0766 | -0.08 | -0.32 | -0.24 | -0.37 | 8.23 |
| Estimated EPS | 0 | 0 | None | 0.04 | 0.04 | 0.03 | 0.03 | -0.13 | -0.05 | -0.07 | 0.06 | -1.11 |
| Surprise | 0 | 0.05 | 0 | -0.0181 | -0.0928 | -0.1245 | -0.1066 | 0.05 | -0.27 | -0.17 | -0.43 | 9.34 |
| Surprise Percentage | None% | None% | None% | -45.25% | -232% | -415% | -355.3333% | 38.4615% | -540% | -242.8571% | -716.6667% | 841.4414% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TXMD
2025-10-19 16:44:00
TherapeuticsMD Inc. (TXMD) stock increased by 12.92% following news of a strategic partnership to expand operations into European markets. Despite a mixed financial picture with past revenue declines, the company shows strong gross margins and healthy financial strength, leading to cautiously optimistic investor sentiment. Analysts are focusing on the potential for revenue growth in new markets and improved operational efficiencies as critical factors for future performance.
2025-10-18 16:47:00
TherapeuticsMD Inc. (TXMD) stock surged by 12.92% following promising FDA designations and market speculations about potential acquisition strategies. While the company exhibits strong profitability ratios and financial resilience with a 100% gross margin, concerns remain regarding its negative pretax profit margin and declining revenue growth over the past three and five years. The outlook remains cautious due to a lack of strong bullish catalysts and ongoing operational challenges, despite recent positive market movements.
2025-10-18 16:20:00
TherapeuticsMD Inc. (TXMD) stock surged by 12.92%, driven by positive market sentiment and strategic business moves, despite mixed financial metrics including a 100% gross margin but a -126.1% pretax profit margin. Technical analysis suggests a bullish trend with a potential short-term price target of $1.26, contingent on maintaining support above $1.12. The company's improved financial health is also evidenced by its current ratio of 2.9 and increased cash reserves, pointing towards cautious optimism for future growth.
2025-10-17 08:02:54
This page from TradingView provides financial data for TherapeuticsMD, Inc. (A3DL7E) specifically focusing on the operating cash flow per share. It lists the period, value, change, and change percentage for this financial metric. The article indicates that there are no current trades for the stock on Lang & Schwarz Tradecenter.
2022-07-13 18:57:32
A planned deal for EW Healthcare Partners to acquire TherapeuticsMD for $10 a share, or approximately $177 million, has unraveled due to insufficient shareholder support. Only 30% of shares were tendered, falling short of the required amount. TherapeuticsMD announced it would terminate the merger and continue normal operations, causing its shares to fall over 40%.
2022-07-13 06:50:00
TherapeuticsMD announced that the tender offer by Athene Merger, Inc., an affiliate of EW Healthcare Partners, has expired because it failed to acquire the required majority of shares. As a result, TherapeuticsMD anticipates that the Merger Agreement will be terminated, though the company intends to maintain normal operations. Greenhill & Co., LLC served as financial advisor, and DLA Piper LLP (US) and Jones Day served as legal counsel to TherapeuticsMD.
